Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cysteine proteinase inhibitors decrease articular cartilage and bone destruction in chronic inflammatory arthritis

R E Esser1, R A Angelo, M D Murphey

  • 1Marion Merrell Dow Research Institute, Kansas City, Missouri.

Arthritis and Rheumatism
|February 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2.

Journal of veterinary pharmacology and therapeutics·2009
Same author

A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2008
Same author

Radiology corner. Answer to last month's radiology case and image: Brodie abscess.

Military medicine·2007
Same author

Case for diagnosis. Brodie abscess.

Military medicine·2007
Same author

Solitary osteosclerotic plasmacytoma: association with demyelinating polyneuropathy and amyloid deposition.

Skeletal radiology·2001
Same author

Angiomatosis of bone with localized mineralization defect.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2001
Same journal

Proceedings of the Annual Meeting of the American Rheumatism Association.

Arthritis and rheumatism·2020
Same journal

The regional distribution of rheumatologists: what can we do, what should we do?

Arthritis and rheumatism·2013
Same journal

Regional distribution of adult rheumatologists.

Arthritis and rheumatism·2013
Same journal

Clinically significant renal involvement in primary Sjögren's syndrome: clinical presentation and outcome.

Arthritis and rheumatism·2013
Same journal

Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study.

Arthritis and rheumatism·2013
Same journal

Association of low baseline levels of erythrocyte folate with treatment nonresponse at three months in rheumatoid arthritis patients receiving methotrexate.

Arthritis and rheumatism·2013
See all related articles

Peptidyl fluoromethyl ketones effectively inhibited cysteine proteinases, significantly reducing joint disease severity and tissue destruction in experimental arthritis models. These findings highlight their therapeutic potential for inflammatory joint diseases.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Rheumatology

Background:

  • Cysteine proteinases, including cathepsins B and L, play a role in inflammatory joint diseases.
  • Cartilage and bone destruction are key pathological features of arthritis.

Purpose of the Study:

  • To evaluate the efficacy of peptidyl fluoromethyl ketones as inhibitors of cathepsins B and L.
  • To assess the impact of these inhibitors on cysteine proteinase activity in tissues.
  • To determine their effects on cartilage and bone destruction in experimental arthritis.

Main Methods:

  • In vitro inhibition assays using purified cathepsins B and L and fluorogenic substrates.
  • Ex vivo assessment of tissue cysteine proteinase activity following oral fluoroketone administration.

Related Experiment Videos

  • In vivo studies using animal models of arthritis (adjuvant-induced and type II collagen-induced), with clinical, histologic, and radiologic evaluations.

    • Main Results:

    • Fluoroketones demonstrated potent inhibition of purified cathepsins B and L in vitro.
    • Oral administration reduced ex vivo tissue cysteine proteinase activity by up to 77%.
    • Fluoroketone treatment significantly ameliorated clinical signs of arthritis and reduced cartilage and bone destruction, with notable improvements in soft tissue changes, periosteal proliferation, and bone erosion.

    Conclusions:

    • Peptidyl fluoromethyl ketones are effective inhibitors of cysteine proteinases.
    • These inhibitors show promise in limiting tissue destruction in inflammatory joint diseases like rheumatoid arthritis.